A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Polatuzumab vedotin (Primary) ; Bendamustine; Obinutuzumab; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Aug 2018 Planned End Date changed from 11 Jul 2021 to 12 Jul 2021.
    • 02 Jul 2018 Planned number of patients changed from 224 to 250.
    • 02 Jul 2018 Planned End Date changed from 13 Jun 2019 to 11 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top